Stonepine Capital Management

Mr. Plexico, the founder and principal, leads investment decisions. He is supported by Mr. Carroll, who serves as Director of Research and has evaluated life-science opportunities at Stonepine for twelve years. The firm's governance is lean; Mr. Nunnenkamp, the COO and CCO, oversees operations and compliance.

Stonepine draws on deep sector networks built over decades. Mr. Plexico's prior role at Merriman Curhan Ford & Co. focused on PIPEs and secondary offerings, while Mr. Fong's background includes co-heading venture capital at Burrill & Company, which managed over $1 billion. Their board seats at companies like ADMA Biologics and Viveve Medical further embed them in life-science deal flow.

Stonepine targets both. The firm actively participates in private investments in public equity (PIPEs) and secondary offerings, as well as direct private placements. Its emphasis leans toward small to mid-cap biotechnology companies, often at the commercial or late-clinical stage.

The firm emphasizes commercial-stage life-science companies, according to its Director of Research, Mr. Carroll. Principals' board experience spans both early commercial entities and more mature public companies, giving them latitude across pre-revenue and revenue-generating stages within biotechnology and medtech.

Mr. Fong, a firm principal, is a co-founder and managing partner of Biomark Capital, a life-science venture firm. He previously served as co-head of venture capital and general partner at Burrill & Company. While Stonepine is a separate legal entity, the shared leadership creates an overlapping network and investment philosophy across the three firms.